Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 1.205
-3.23 %
$ 32.7 M
Market Cap
-1.41
P/E
1. INTRINSIC VALUE
Balance Sheet
Femasys Inc.
| Current Assets | 8.02 M |
| Cash & Short-Term Investments | 3.45 M |
| Receivables | 488 K |
| Other Current Assets | 4.08 M |
| Non-Current Assets | 4.42 M |
| Long-Term Investments | 0 |
| PP&E | 3.4 M |
| Other Non-Current Assets | 1.02 M |
| Current Liabilities | 8.58 M |
| Accounts Payable | 1.42 M |
| Short-Term Debt | 5.92 M |
| Other Current Liabilities | 1.24 M |
| Non-Current Liabilities | 1.56 M |
| Long-Term Debt | 1.52 M |
| Other Non-Current Liabilities | 39.6 K |
EFFICIENCY
Earnings Waterfall
Femasys Inc.
| Revenue | 1.63 M |
| Cost Of Revenue | 545 K |
| Gross Profit | 1.08 M |
| Operating Expenses | 18.9 M |
| Operating Income | -17.8 M |
| Other Expenses | 1.03 M |
| Net Income | -18.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Femasys Inc.
| Net Income | -18.8 M |
| Depreciation & Amortization | 852 K |
| Capital Expenditures | -762 K |
| Stock-Based Compensation | 444 K |
| Change in Working Capital | -3.14 M |
| Others | 240 K |
| Free Cash Flow | -20.2 M |
Wall Street Analysts Price Targets
Femasys Inc.
FEMY has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
FEMY does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Femasys Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.19 per share a year ago.
zacks.com
- 1 month ago
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
-- Company expands commercial product offering with FemBloc ® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update.
globenewswire.com
- 1 month ago
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option Femasys continues to expand access and market share for its first-line infertility treatment option
globenewswire.com
- 1 month ago
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the Company has secured strategic distribution partnerships for FemBloc® in Spain. Comercial Medico Quirurigca, SA (CMQ) will expand its commercial portfolio to include FemBloc, alongside other Femasys products in northern Spain, while Durgalab will handle distribution in the southern region.
globenewswire.com
- 1 month ago
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
First-in-world approval of FemBloc delivery system for women seeking permanent birth control First-in-world approval of FemBloc delivery system for women seeking permanent birth control
globenewswire.com
- 1 month ago
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the peer-reviewed publication of positive data from its initial clinical trials of FemBloc® permanent birth control in the Journal of Gynecology & Reproductive Medicine (JGRM) , a leading peer-reviewed journal covering gynecology and reproductive medicine.
globenewswire.com
- 2 months ago
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Medicines & Healthcare products Regulatory Agency (MHRA) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection. “This is another key milestone as we expand our reach to the UK following successful approval across Europe for our innovative infertility and cancer detection products.
globenewswire.com
- 2 months ago
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception
globenewswire.com
- 3 months ago
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
FemaSeed® patent application provides additional coverage for Femasys' therapeutic option for women seeking infertility solution
globenewswire.com
- 3 months ago
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients
globenewswire.com
- 5 months ago
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.26 per share a year ago.
zacks.com
- 5 months ago
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
globenewswire.com
- 5 months ago
8. Profile
Summary
Femasys Inc. FEMY
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 32.7 M
Dividend Yield
0.00%
Description
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Contact
3950 Johns Creek Court, Suwanee, GA, 30024
https://www.femasys.com
IPO
Date
June 18, 2021
Employees
69
Officers
Ms. Kathy Lee-Sepsick M.B.A.
Founder, President, Chief Executive Officer & Director
Mr. Daniel Scott Currie
Chief Operating Officer, Senior Vice President & Secretary
Ms. Mary An Merchant J.D., Ph.D.
Vice President of Counsel & Intellectual Property
Ms. Naomi Phaneuf
Vice President of Marketing
Ms. Christine Thomas
Senior Vice President of Regulatory & Clinical Affairs
Mr. Benjamin Dings
Vice President of Sales
Mr. Dov Elefant
Chief Financial Officer
Dr. Jeffrey Marcus M.D., M.S.
Chief Medical Advisor
Mr. Richard Spector
Chief Commercial Officer
Dr. James H. Liu M.D.
Chief Medical Officer